Literature DB >> 8917822

Tolerance to intravenous administration of heparin and heparinoid in a patient with delayed-type hypersensitivity to heparins and heparinoids.

W H Boehncke1, L Weber, H Gall.   

Abstract

Delayed-type hypersensitivity reactions to subcutaneously (s.c.) injected heparins are common. Since similar reactions usually occur to different heparin preparations, semisynthetic heparinoids might be a therapeutic alternative. We report a patient exhibiting eczematous reactions to heparins as well as heparinoids; delayed-type hypersensitivity was demonstrated by intracutaneous (i.c.) and patch tests, as well as by s.c. provocation. Remarkably, intravenous (i.v.) administration of heparin as well as heparinoid was well-tolerated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8917822     DOI: 10.1111/j.1600-0536.1996.tb02293.x

Source DB:  PubMed          Journal:  Contact Dermatitis        ISSN: 0105-1873            Impact factor:   6.600


  5 in total

1.  [Delayed intracutaneous test reaction in heparin intolerance].

Authors:  G Wurpts; H F Merk
Journal:  Hautarzt       Date:  2007-05       Impact factor: 0.751

2.  [Dermal necrosis as cutaneous manifestation of heparin-induced thrombocytopenia II?].

Authors:  M Illes; S Klaus; J C Simon; R Treudler
Journal:  Hautarzt       Date:  2011-04       Impact factor: 0.751

3.  Low allergenic potential with fondaparinux: results of a prospective investigation.

Authors:  Marc Schindewolf; Julia Scheuermann; Hartmut Kroll; Jurate Garbaraviciene; Carola Hecking; Ingo Marzi; Manfred Wolter; Roland Kaufmann; Wolf-Henning Boehncke; Edelgard Lindhoff-Last; Ralf J Ludwig
Journal:  Mayo Clin Proc       Date:  2010-09-15       Impact factor: 7.616

Review 4.  Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

5.  The concept of "compartment allergy": prilocaine injected into different skin layers.

Authors:  Marion Wobser; Zeno Gaigl; Axel Trautmann
Journal:  Allergy Asthma Clin Immunol       Date:  2011-04-20       Impact factor: 3.406

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.